Intra-Cellular Therapies Challenges Approval of Caplyta Generics with Lawsuits
Tuesday, 2 April 2024, 19:38
Intra-Cellular Therapies Files Lawsuits Against Caplyta Generics
In a strategic move, Intra-Cellular Therapies (ITCI) has taken legal action against manufacturers seeking approval for generics of its primary product, Caplyta. This decision has led to a notable decline in ITCI stock prices.
Key Points:
- Intra-Cellular Therapies (ITCI) has filed lawsuits challenging manufacturers of Caplyta generics.
- The legal actions have caused a significant drop in ITCI stock price.
- This move indicates Intra-Cellular Therapies' determination to protect its market share and product exclusivity.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.